MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.423
- +0.014+3.35%
Close Dec 20 16:00 ET
- 0.409
- -0.014-3.24%
Post 19:59 ET
23.18MMarket Cap-0.24P/E (TTM)
0.460High0.340Low5.36MVolume0.344Open0.409Pre Close2.16MTurnover11.45%Turnover RatioLossP/E (Static)54.86MShares1.15052wk High32.51P/B19.77MFloat Cap0.22652wk Low--Dividend TTM46.79MShs Float29.647Historical High--Div YieldTTM29.37%Amplitude0.226Historical Low0.403Avg Price1Lot Size
About Cara Therapeutics Company
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Company Profile
SymbolCARA
Company NameCara Therapeutics
Listing DateJan 31, 2014
Issue Price11.00
Founded2004
CEOMr. Christopher A. Posner
MarketNASDAQ
Employees55
Fiscal Year Ends12-31
Address400 Atlantic Street,Suite 500
CityStamford
ProvinceConnecticut
CountryUnited States of America
Zip Code06901
Phone1-203-406-3700
Company Executives
- Name
- Position
- Salary
- Christopher A. Posner
- President, Chief Executive Officer and Director
- 2.92M
- Scott M. Terrillion
- General Counsel, Secretary and Chief Compliance Officer
- --
- Ryan D. Maynard
- Chief Financial Officer and Principal Accounting Officer
- 1.24M
- Martin A. Vogelbaum
- Chairman of the Board
- 519.99K
- Dr. Jeffrey L. Ives, PhD
- Independent Director
- 272.49K
- Helen M. Boudreau, M.B.A.
- Independent Director
- 376.01K
- Dr. Lisa von Moltke, M.D.
- Independent Director
- 254.99K
- Dr. Susan Shiff, M.B.A.,PhD
- Independent Director
- 262.49K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.